Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Canakinumab improves survival in advanced NSCLC
Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.
Canakinumab improves survival in advanced NSCLC
07 Oct 2023COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?
Mental health symptoms of family members of patients hospitalized for acute respiratory distress syndrome (ARDS) were similar at 12 months regardless of whether it was caused by COVID-19 or not, a prospective cohort study suggests.
COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?
04 Oct 2023Serplulimab-chemo shows promise for squamous NSCLC
Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.
Serplulimab-chemo shows promise for squamous NSCLC
03 Oct 2023Low visceral fat area predicts poor survival in cancer patients
Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.
Low visceral fat area predicts poor survival in cancer patients
02 Oct 2023Living near a major road may accelerate lung function decline in IPF patients
People with idiopathic pulmonary fibrosis (IPF) who live near a major road tend to have a faster decrease in lung function, according to a study in Australia. Likewise, increased exposure to fine particulate matter (<2.5 μm, PM2.5) is associated with a higher rate of annual decline in diffusing capacity of the lungs for carbon monoxide (DLco).
Living near a major road may accelerate lung function decline in IPF patients
02 Oct 2023Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).
Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
02 Oct 2023Pretreatment serum CEA level predicts survival in NSCLC
Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.